Topic resource collection
Approved comparison material connected to this topic.
33 resourcesRead both sides
ACE-031 vs Follistatin for Muscle Research UK 2026 All peptides and proteins discussed in this article are supplied strictly for in vitro and in vivo laboratory research use only (RUO). None are approved for All peptides and prot…
ACE-031 vs Follistatin: comparing research profiles Both ACE-031 and Follistatin inhibit myostatin and activin signalling, but through different mechanisms and with distinct pharmacological profiles. This post Both ACE-031 and Fo…
ACE-031 and Follistatin both effectively block the myostatin/activin superfamily Smad2/3 pathway in skeletal muscle, producing quantitatively similar outcomes in myostatin-only challenge models (myotube diameter, MHC expression, …
Both ACE-031 and Follistatin inhibit myostatin and activin signalling, but through different mechanisms and with distinct pharmacological profiles. This post compares these two approaches, helping researchers select the appropria…
The distinction between physiological and pathological cardiac hypertrophy is mechanistically critical for interpreting ACE-031’s cardiac biology. Physiological hypertrophy (exercise-induced, pregnancy-associated) is driven by PI…
It’s important to emphasise that ACE-031 is not a peptide in the traditional sense. Key differences include: Molecular Weight: ~80 kDa (much larger than peptides, which are typically <10 kDa) Production: Made via mammalian cell e…
Myostatin-specific antibodies represent another mechanistic approach to myostatin inhibition. Unlike ACE-031’s soluble receptor strategy: Antibodies: Directly bind myostatin protein itself ACE-031: Acts as decoy receptor, competi…
Muscle growth magnitude: ACE-031: 50-100% improvements in muscle mass and strength in animal models Follistatin: Similar or slightly greater improvements (broader TGF-β inhibition) Difference: Modest; both are effective Disease m…
Visceral adipose tissue (VAT) is the metabolically deleterious fat depot — associated with insulin resistance, ectopic lipid deposition, adipose tissue macrophage (ATM) infiltration, and pro-inflammatory cytokine production (IL-6…
ACE-031 adverse effects: Epistaxis and telangiectasia (vascular; most common) Injection site reactions (expected; minimal) Immunogenicity (low-titre antibodies in minority) Follistatin adverse effects: Epistaxis (observed in some…
All peptides and proteins discussed in this article are supplied strictly for in vitro and in vivo laboratory research use only (RUO). None are approved for human therapeutic use, and none of the data presented constitute medical…
Lyophilised (freeze-dried) ACE-031: More stable for long-term storage (months-years at 2-8°C) Requires reconstitution before use Less immunogenic debris in formulation Recommended for long-term inventory or less frequent use Liqu…
Both ACE-031 and Follistatin inhibit myostatin and activin signalling, but through different mechanisms and with different characteristics: Molecular Type Fusion protein (80 kDa) Peptide (37-44 kDa) Target Specificity Myostatin, …
An important distinction: Myostatin knockout: Zero myostatin; maximal muscle growth but some off-target effects ACE-031 inhibition: Partial myostatin inhibition; dose-titratable growth promotion Clinical relevance: Partial inhibi…
ACE-031 is one of several myostatin pathway inhibitors that have been investigated in ALS or related muscle-wasting contexts. Key comparators include: Anti-myostatin antibodies (landogrozumab, domagrozumab, trevogrumab): Myostati…
For myostatin-selective research (studying GDF-8-specific biology, myostatin dose-response, genetic myostatin-null comparison contexts), neither ACE-031 nor FST-288 is the ideal tool — both capture multiple ligands. Anti-myostati…
Follistatin vs ACE-031 for Muscle Research UK 2026 Follistatin and ACE-031 (modified ActRIIB-Fc) are supplied for research and laboratory use only. Neither is licensed for human therapeutic use in the UK. All Follistatin and ACE-…
Follistatin vs ACE-031: comparing myostatin inhibition research Two principal strategies for antagonising myostatin in research are Follistatin and ACE-031. Both promote muscle growth through myostatin inhibition, but they Two pr…
This is crucial for understanding why ACE-031 works differently than compounds like MGF: Growth factors (MGF, IGF-1) Bind receptors; activate growth signalling Stimulate (push growth) Myostatin inhibitors (ACE-031) Remove growth …
ACE-031 is sometimes compared to myostatin knockouts. How do they differ? Knockout: Permanent genetic removal of myostatin; effects are irreversible ACE-031: Temporary pharmacological inhibition; reversible upon clearance Degree …